Charting Solar’s Path
Amid an escalating trade war and increasing market volatility, one of the very few ‘bright spots’ in the markets – outside of precious metals –… Read More »Charting Solar’s Path
Amid an escalating trade war and increasing market volatility, one of the very few ‘bright spots’ in the markets – outside of precious metals –… Read More »Charting Solar’s Path
Two small biotech companies focused on underserved medical needs and patient populations – including neuropsychiatric/neurological disorders and women’s health issues – are among five Buy-rated… Read More »Big Upside Potential At Low Prices For Aggressive Traders
What has happened to some of the most promising (and popular) marijuana stocks? Here’s a look at three beaten-down pot stocks – and whether they… Read More »Beaten Down In A Budding Space
While the Trump Administration has delayed implementation of its most recently announced tariffs on Chinese goods because of concerns about their potential impact on the… Read More »Protracted Trade War? There’s ETFs For That!
If you’re still getting your feet wet in the pot stock pool, the best stocks to consider may be the biggest players in the market.… Read More »The Biggest Players In Pot
As it has consistently done in advance of past recessions, the yield curve recently inverted, with the yield on 10-year Treasury bonds dipping below the… Read More »Inversion Strategy
With the global operating room equipment market surpassing $29 billion in 2018, and expected to see year-over-year growth of 6% this year, rising operating room… Read More »Opportunity In The Operating Room
While there has been a broad sell-off of marijuana stocks, many have been bucking this trend and hitting new highs. And some of the marijuana… Read More »Sold-Off Cannabis Stocks – And The Hedge Funds That Love Them
Despite the bond market rally, one strategist is sharing a contrarian scenario that would see rates go higher – and has identified a number of… Read More »A Contrarian Thesis On Rates – And Several Ways To Play It
With drug candidates in clinical development for in vitro fertilization, endometriosis and more, this Swiss-based, clinical-stage biopharma company is focused on the creation and commercialization… Read More »A Women’s Health Stock Analysts (And Insiders) Are Loving, But The Market Is Ignoring